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osting by EAbstract Hypothyroidism is a common disorder that confers an increased cardiovascular risk. The
most common cause is Hashimoto thyroiditis (HT) but it can also be caused by thyroidectomy and
radioiodine therapy. The aim of the study is to examine whether there is a relation between the
cause of hypothyroidism and cardiovascular risk.
Subjects and methods: The study included 20 patients with Hashimoto thyroiditis and hypothyroid-
ism, 20 patients with post-thyroidectomy hypothyroidism, 20 patients with post-radioiodine hypo-
thyroidism, and 20 age and sex matched controls. In all the studied subjects we determined thyroid
function tests; TSH and F.T4, thyroid auto-antibodies; anti-TPO and anti-TG antibodies, carotid
intima media thickness (CIMT), ﬂow mediated dilation (FMD) and serum nitric oxide.
Results: CIMT showed a trend to be higher in HT group (0.93 ± 0.08 mm) compared to other
causes of hypothyroidism (P= 0.090). Multivariate analysis showed that HT is an independent
predictor of CIMT (P= 0.015). FMD was signiﬁcantly lower in HT group (5.74 ± 1.33%)
compared to post-thyroidectomy (7.16 ± 1.05%) (P= 0.001), and post-radioiodine therapy
(7.34 ± 1.34%) (P= 0.000). Multivariate analysis showed that HT is an independent predictor
of FMD (P= 0.000). NO was signiﬁcantly higher in hypothyroid patients (125.98 ± 5.03 lM/media thickness; FMD, ﬂow
oiditis; NO, nitric oxide
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268 M.N. Atta et al.ml) compared to controls (39.44 ± 3.63 lM/ml) (P= 0.001), both univariate and multivariate
analyses showed that NO is an independent predictor of both CIMT and FMD (P= 0.000).
Conclusion: To our knowledge, this is the ﬁrst study to show that Hashimoto thyroiditis is an inde-
pendent cardiovascular risk factor in clinically hypothyroid patients.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Hypothyroidism is the most common pathological hormonal
deﬁciency and is more common in females and the elderly.1
Overt hypothyroidism in the general population occurs in
about 0.3% reaching 1.7% in elderly individuals P65 years
and up to 2% in women older than 60 years of age.2,3
Prevalence of subclinical hypothyroidism differs according
to the studied population, from 4.3% to 8.5% in patients with-
out history of thyroid disease 2,4 reaching 20% in females more
than 65 years of age and up to 16% of males and 21% of
females older than 74 years.4
Autoimmune thyroiditis (AIT) is an inﬂammatory condi-
tion of the thyroid gland characterized by intrathyroidal
lymphocytic inﬁltration, ultrasonographic signs of inﬂamma-
tion and antibodies to thyroglobulin, thyroperoxidase (TPO)
or both. AIT includes Hashimoto’s thyroiditis, painless post-
partum thyroiditis and painless sporadic thyroiditis.5 A diag-
nosis of Hashimoto’s thyroiditis is made when there is a
diffuse swelling of the thyroid without any other cause in
addition to any of the following: positive for anti-thyroid
peroxidase antibodies, positive for anti-thyroglobulin
antibodies or the presence of lymphocytic inﬁltration of
the thyroid gland.6
Predictors of hypothyroidism in HT include: female sex,
high normal TSH > 2.5 is the strongest predictor of hypothy-
roidism with the prevalence of hypothyroidism being 12% with
baseline TSH of 2.5 and 87.5% with a baseline TSH of 4 and
lastly positive anti-thyroid antibodies.7
Thyroidectomy operation may be total thyroidectomy (TT)
in which the entire thyroid gland is removed or partial thyroid-
ectomy which is further subdivided into: (1) near total thyroid-
ectomy (NT), where less than 3 g of the gland is left behind; (2)
subtotal thyroidectomy (ST), where no more than 25% of a
single lobe is left and (3) hemithyroidectomy (HT) or lobec-
tomy, where only one lobe is excised.8
Total thyroidectomy, by deﬁnition, causes hypothyroidism;
near total thyroidectomy causes hypothyroidism in 85–100%.9
Occurrence of hypothyroidism following subtotal thyroidec-
tomy depends on a number of factors: age (there is a positive
relation between age and thyroid function),10 gender (there is a
negative relation between male gender and thyroid function),10
thyroid remnant volume/weight; the only modiﬁable factor
(there is a strong negative correlation between remnant volume
and TSH)11 and ultrasound aspect of the thyroid remnant
(hypoechoec aspect on ultrasound which may be due to inﬂam-
matory alterations) strongly predicted hypothyroidism. When
ultrasound aspect and weight of the remnant are combined
minimal thyroid remnant volume required to prevent hypothy-
roidism in isoechoec aspect is 4.2 ml).11
Occurrence of hypothyroidism following hemithyroidec-
tomy depends on a number of factors: marked lymphocytic
inﬁltration (grade 3 or 4),12–14 preoperative TSH > 2–3,15detectable TPO Ab and Tg Ab,16–18 Hashimoto’s thyroiditis
and MNG,19,20 remnant lobe volume 6 4 ml,21 long standing
disease before operation,16 low iodine intake status,22 low ini-
tial free T423 and right hemithyroidectomy.24
Radioiodine has been used for the treatment of hyperthy-
roidism since 1940; it is used for the treatment of hyperthyroid-
ism due to Grave’s disease or toxic multinodular goiter.25,26 It
is considered the 1st line treatment for Grave’s disease and the
treatment of choice for relapsed Grave’s and toxic MNG.27
The optimum outcome is to achieve euthyroidism without
relapse or hypothyroidism. However, it is impossible to titrate
the dose of radioiodine to accurately guarantee euthyroidism.28
Predictors of hypothyroidism following radioiodine for
hyperthyroidism include: small thyroid volume, mild hyperthy-
roidism (mildly elevated initial free T4),29 high radioiodine
activity,29–31 Grave’s disease rather than toxic MNG,31,32
higher TSH especially in toxic MNG,32,33 use of recombinant
human TSH (rhTSH),34,35 female gender and older age.29,36
Hypothyroidism is an independent risk factor for myocar-
dial infarction (MI), aortic atherosclerosis and CHD events
and mortality through altering traditional and nontraditional
risk factors for cardiovascular disease; including: dyslipidemia
(high total cholesterol, LDL cholesterol, sd-LDL, [Lp(a)],
chyomicron remnants and a low HDL cholesterol),37,38 hyper-
tension (three times more prevalent in hypothyroidism than in
euthyroid subjects),37 homocysteine (increased in hypothyroid-
ism due to decreased clearance),37 oxidative stress39 and endo-
thelial dysfunction.40
Nitric oxide (NO) is one of themost abundant free-radicals in
the body and excess NO production causes mitochondrial respi-
ratory enzyme inhibition. Although the formed O2 is scavenged
by super oxide dismutase (SOD), NO is the only known biolog-
ical molecule that reacts faster with superoxide and is produced
in high concentrations enough to outcompete endogenous levels
of superoxide dismutase. If NO production is increased, short-
lived NO rapidly reacts with O2 to form a potent and powerful
long-lived oxidant free-radical, peroxynitrite (ONOO) that
decomposes into the hydroxyl radical OH, which is one of
the most active ROS that oxidizes LDL.41
Increased peroxynitrite production, resulted in increased
apoptotic cell death in atheromatous plaques of human coro-
nary arteries.42 Thus when oxidant defenses become depleted
or endogenous tissue rates of oxidant production are acceler-
ated, NO gives rise to secondary oxidizing species that increase
membrane and lipoprotein lipid oxidation as well as foam cell
formation in the vasculature.43
Endothelial cells respond to physical stimuli (e.g., shear
stress), hormones, cytokines, drugs, and substances released
by sensory and autonomic nerves or platelets by producing
vasoactive relaxing substances (e.g. NO) and contracting
substances (e.g. endothelin-1) that regulate vascular tone
and permeability, hemostasis, angiogenesis, and inﬂamma-
tion. The vascular endothelium sustains the balance between
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genesis and ﬁbrinolysis, promotion and inhibition of the
smooth muscle cell proliferation and migration, and also be-
tween vasoconstriction and vasodilation. The disruption of
this tightly controlled balance leads to the development of
endothelial dysfunction which represents a predominant early
feature of atherosclerosis.44
Endothelial dysfunction represents a key early step in the
development of atherosclerosis and is also involved in plaque
progression and the occurrence of atherosclerotic complica-
tions. Endothelial dysfunction signiﬁcantly increased the risk
of vascular events in asymptomatic patients with early stages
of atherosclerosis.45
Evidence supports the view that the endothelial dysfunction
associated with atherosclerosis is related to the local formation
of reactive oxygen and nitrogen species in the vicinity of the
vascular endothelium.44
Impaired brachial artery FMD; a marker of endothelial dys-
function; is an independent predictor of long-term in-stent reste-
nosis after percutaneous intervention PCI,46 incident
cardiovascular events (MI, stroke and death) in an unselected,
multi-ethnic population without a history of myocardial infarc-
tion or stroke47 and postoperative cardiovascular events in pa-
tients undergoing nonemergent vascular surgery.48 It also can
identify subjects with asymptomatic coronary artery disease.49
CIMT (carotid intima media thickness) is a validated tool
for noninvasive measurement of early asymptomatic (subclin-
ical) atherosclerotic disease. Carotid IMT independently pre-
dicts future vascular events (MI, stroke, and cardiovascular
death). Its predictive value is at least as high in younger sub-
jects as in older subjects.50 Increase in CIMT is not only asso-
ciated with the presence of coronary artery disease CAD but
also with the extent of CAD.51
Our aim is to study the relation between the cause of
hypothyroidism, Hashimoto thyroiditis, surgery and radioac-
tive iodine and cardiovascular risk in clinically hypothyroid
patients.
2. Subjects
The study was carried out on 80 subjects attending the Internal
Medicine and the Endocrinology Outpatient Clinics in Alexan-
dria Main University Hospital, who were categorized into four
groups: Group I: included 20 patients with chronic autoim-
mune thyroiditis (diagnosed by anti-thyroid antibodies and
thyroid ultrasound) and hypothyroidism deﬁned as TSH>
7 lIU/ml and F.T4 < 9 pmol/l, Group II: included 20 patients
with post-thyroidectomy hypothyroidism, Group III: included
20 patients with post-irradiation hypothyroidism, Group IV:
included 20 healthy subjects of matched age and sex as a con-
trol group.
Exclusion criteria were patients with a history of diabetes
mellitus, hypertension, familial dyslipedemia, renal failures,
any degree of glucose intolerance and known or symptomatic
cardiovascular disease.
3. Methods
3.1. History and examination
Thorough history taking and complete physical examination
for signs and symptoms of hypothyroidism, cardiovasculardisease, diabetes and hypertension was performed. Height,
weight and waist circumference were measured and BMI was
calculated by the formula wt in kilograms/(ht)2 in meters.
3.2. Assessment of thyroid function and autoimmunity
Thyroid function was assessed by the determination of thyroid-
stimulating hormone (TSH) ELISA, LDN-Germany; reference
range 0.4–7 lIU/ml52 and free T4 (Free L-thyroxine ELISA,
LDN-Germany); reference range 9.0–22.2 pmol/l.53 Thyroid
autoimmunity was assessed by the determination of thyroper-
oxidase antibodies (SERION ELISA classic, Institut Virion/
serion GmbH-Germany); a normal range of less 50 IU/ml
and thyroglobulin antibodies (anti-thyroglobulin ELISA,
LDN-Germany); a normal range of less 100 IU/ml.54
3.3. Assessment of asymptomatic (subclinical) atherosclerotic;
carotid intima media thickness (CIMT)
We assessed the CIMT in compliance with the recommendation
of the American society of echocardiography consensus state-
ment in 2008 for the use of ultrasonography for the measure-
ment of CIMT.55 Longitudinal images from three imaging
planes: anterior, lateral, and posterior with clear images of dis-
tal CCA (distal 1 cm of each CCA) in a perfectly horizontal
plane with double lines on near and far walls, indicating true
perpendicular scanning plane with a linear-array transducer
operating at a fundamental frequency of at least 7 MHz (B-
mode imaging). Mean CIMT values from the far walls of the
right and left CCAs (mean–mean) was reported; Mean–mean
(average of segmental mean CIMT values) values are more
reproducible because multiple points along the traced segment
are averaged. CIMT values greater than or equal to 75th percen-
tile are considered high and indicative of increased CVD risk.56
3.4. Assessment of endothelial function; ﬂow mediated dilation
(FMD)
The subjects were investigated by high-resolution color Dopp-
ler ultrasound imaging of the brachial artery in the dominant
arm in a darkened, temperature controlled room. Further-
more, allowing the participants to rest for 10 min before the
study permits hemodynamic stabilization and thus guarantees
more accurate baseline readings.
Subjects were instructed to refrain from alcohol and stren-
uous exercise for 24 h prior to the study, abstain from smok-
ing, vasoactive medicine, caffeine and high-fat food for at
least 2 h, as these can all affect FMD.
The study was performed with subjects resting in the supine
position. Study participants fasted for 8 h prior to the exam. The
subjects’ dominant arm was comfortably immobilized in the ex-
tended position to allow consistent access to the brachial artery.
For each subject, optimal brachial artery images were obtained
approximately 5 cm above the antecubital fossa. Arm pressure
was caused by inﬂating a pneumatic arm cuff up to 50 mm Hg
higher than the subject’s systolic arterial pressure for 5 min.
Doppler ultrasound measurements were performed before and
60 s after reactive hyperemia. To avoid interobserver variability,
all measurements were performed by the same examiner, who
was blind to the subjects’ clinical status.
The internal diameter of the brachial artery (at the intima–
lumen interface) was assessed at the end of diastole. The
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and the peak as the mean of three consecutive images mea-
sured at the time of the maximal increase in diameter after cuff
release and the values were recorded.
FMD was calculated according to the formula:
FMD= (post-occlusion diameter  baseline diameter) · 100/
baseline diameter.57
3.5. Assessment of oxidative stress; serum nitric oxide (NO)
Nitric oxide levels were determined with a colorimetric method
based on the Griess reaction. Sodium nitrite was used as a
standard, and the results were expressed as lM/ml.58Table 2 Clinical and laboratory characteristics of hypothy-
roid patients compared to control.
Hypothyroid Control P
Age (Y) 41.85 ± 9.50 41.40 ± 9.75 0.936
BMI 25.91 ± 1.46 25.70 ± 1.34 0.766
WC (cm) 89.15 ± 7.23 86.30 ± 6.47 0.286
Urea (mg/dl) 35.65 ± 3.41 19.65 ± 2.14 0.001
Creatinine (mg/dl) 0.96 ± 0.04 0.76 ± 0.06 0.001
FPG (mg/dl) 90.82 ± 5.60 79.70 ± 5.27 0.001
Hb 11.96 ± 1.39 13.20 ± 0.66 0.001
TC (mg/dl) 262.05 ± 30.66 193.35 ± 14.58 0.001
TG (mg/dl) 140.37 ± 39.19 107.40 ± 18.03 0.001
HDL (mg/dl) 53.18 ± 10.30 54.80 ± 6.93 0.747
LDL (mg/dl) 173.00 ± 22.49 114.50 ± 14.64 0.001
TSH (lIU/ml) 34.06 ± 8.67 2.69 ± 1.81 0.001
Free T4 (pmol/l) 7.21 ± 1.21 14.47 ± 2.48 0.001
Anti-TPO (IU/ml) 74.07 ± 38.82 28.15 ± 9.44 0.001
Anti-TG (IU/ml) 195.12 ± 427.04 8.43 ± 7.26 0.112
NO (lM/ml) 125.98 ± 5.03 39.44 ± 3.63 0.001
CIMT (mm) 0.90 ± 0.08 0.67 ± 0.06 0.001
FMD (%) 6.75 ± 1.42 14.28 ± 1.65 0.0014. Results
All studied groups were matched for age, sex, BMI and waist
circumference. (Tables 1 and 2).
None of our subjects had renal impairment nor impaired
glucose tolerance although there were statistically signiﬁcant
higher levels of FPG, urea and creatinine in hypothyroid pa-
tients compared to control, these parameters also showed a
signiﬁcant negative correlation with F.T4 and a positive corre-
lation with TSH (Tables 1, 2 and 4).
Total cholesterol, low density lipoprotein (LDL) choles-
terol and triglycerides (TG) showed statistically signiﬁcant
higher levels in hypothyroid subjects than in control group
(P= 0.001) (Tables 1 and 2).
Statistical analysis shows that there was no signiﬁcant dif-
ference in the mean high density lipoprotein (HDL) cholesterol
between all studied groups (P= 0.960) (Tables 1 and 2).
Anti-TPO antibodies were signiﬁcantly higher in hypothy-
roidism than in the control group (P= 0.001), also signiﬁ-
cantly higher in HT than in other studied groups (Tables 1–3).
Anti-TG antibodies were signiﬁcantly higher in hypothy-
roidism than control group (P= 0.007), also signiﬁcantly
higher in HT than in other studied groups (Tables 1–3).Table 1 Clinical and laboratory characteristics of the studied grou
Group I Group II
Age (Y) 42.05 ± 9.54 41.30 ± 9.62
BMI 25.91 ± 1.44 25.98 ± 1.51
WC (cm) 87.80 ± 6.76 90.15 ± 7.59
Urea (mg/dl) 35.20 ± 3.59 37.23 ± 3.61
Creatinine (mg/dl) 0.95 ± 0.04 0.98 ± 0.05
FPG (mg/dl) 91.25 ± 5.73 90.90 ± 5.34
Hb 11.75 ± 1.40 12.00 ± 1.48
TC (mg/dl) 278.50 ± 20.28 265.40 ± 24.50
TG (mg/dl) 143.30 ± 40.62 136.90 ± 39.07
HDL (mg/dl) 53.55 ± 11.00 52.90 ± 10.10
LDL (mg/dl) 187.90 ± 9.43 177.70 ± 15.81
TSH (lIU/ml) 39.58 ± 2.01 37.29 ± 3.76
Free T4 (pmol/l) 7.35 ± 1.23 6.65 ± 1.40
Anti-TPO (IU/ml) 111.05 ± 15.07 51.00 ± 26.90
Anti-TG (IU/ml) 461.55 ± 662.00 70.09 ± 88.05
NO (lM/ml) 125.23 ± 5.16 126.72 ± 4.78
CIMT (mm) 0.93 ± 0.08 0.89 ± 0.07
FMD (%) 5.74 ± 1.33 7.16 ± 1.05
Group I: Hashimoto thyroiditis, Group II: post-thyroidectomy hypothyrThyroid ultrasound: Group I demonstrated 70% diffuse
hypoechogenicity, 10% showed atrophic gland, 25% diffuse
goiter and 10% multinodular goiter.
CIMT was signiﬁcantly higher in hypothyroidism than con-
trol group (P= 0.001). CIMT was non-signiﬁcantly (a trend to
increase) higher in HT compared to post-thyroidectomy and to
post-RAI (P= 0.090) (Tables 1–3).
FMD was signiﬁcantly lower in hypothyroidism than con-
trol group (P= 0.001), also FMD was signiﬁcantly lower in
HT compared to post-thyroidectomy (P= 0.000) and to
post-RAI (P= 0.001) (Tables 1–3).
Serum nitric oxide was signiﬁcantly higher in hypothyroid-
ism than control group (P= 0.001) (Tables 1 and 2).ps and control.
Group III Group IV P
42.20 ± 9.82 41.40 ± 9.75 0.994
25.84 ± 1.49 25.70 ± 1.34 0.96
89.50 ± 7.49 86.30 ± 6.47 0.448
34.52 ± 2.47 19.65 ± 2.14 0.001
0.94 ± 0.03 0.76 ± 0.06 0.001
90.30 ± 5.96 79.70 ± 5.27 0.001
12.13 ± 1.35 13.20 ± 0.66 0.001
242.25 ± 34.61 193.35 ± 14.58 0.001
140.90 ± 39.63 107.40 ± 18.03 0.001
53.10 ± 10.32 54.80 ± 6.93 0.960
153.40 ± 23.89 114.50 ± 14.64 0.001
25.33 ± 9.59 2.69 ± 1.81 0.001
7.65 ± 0.74 14.47 ± 2.48 0.001
60.15 ± 39.05 28.15 ± 9.44 0.001
172.48 ± 428.37 8.43 ± 7.26 0.007
125.99 ± 5.27 39.44 ± 3.63 0.001
0.88 ± 0.07 0.67 ± 0.06 0.001
7.34 ± 1.34 14.28 ± 1.65 0.001
oidism, Group III: post-RAI hypothyroidism, Group IV: control.
Table 3 Important (signiﬁcant) differences between HT group and post-thyroidectomy hypothyroidism and post-RAI hypothyroid-
ism groups.
Dependent variable (I) Diagnosis (J) Diagnosis Mean diﬀerence (IJ) Sig.
TC HT RAI 36.2500(*) 0.000
SUR 13.1000 0.132
LDL HT RAI 34.5000(*) 0.000
SUR 10.2000 0.069
TSH HT RAI 14.2550(*) 0.000
SUR 2.2950 0.236
Anti-TG HT RAI 289.0665 0.068
SUR 391.4555(*) 0.014
Anti-TPO HT RAI 50.9000(*) 0.000
SUR 60.0500(*) 0.000
FMD HT RAI 1.5975(*) 0.000
SUR 1.4240(*) 0.001
HT: Hashimoto thyroiditis, SUR: post-thyroidectomy hypothyroidism, RAI: post-RAI hypothyroidism.
*The mean difference is signiﬁcant at the .05 level.
Table 4 Important correlations between studied parameters
and NO, FMD and CIMT in patients with hypothyroidism.
NO CIMT FMD
WC
r 0.191 0.253(*) 0.125
P 0.057 0.011 0.214
FPG
r 0.443(**) 0.470(**) 0.497(**)
P 0.000 0.000 0.000
TG
r 0.299(**) 0.224(*) 0.288(**)
P 0.003 0.025 0.004
TC
r 0.642(**) 0.630(**) 0.826(**)
P 0.000 0.000 0.000
LDL
r 0.704(**) 0.689(**) 0.911(**)
P 0.000 0.000 0.000
Age
r 0.034 0.566(**) 80.003
P 0.734 0.000 0.977
F.T4
r 0.725(**) 0.749(**) 0.799(**)
P 0.000 0.000 0.000
TSH
r 0.822(**) 0.725(**) 0.910(**)
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and anti-TPO antibodies (r= 0.474) which was signiﬁcant
(P= 0.000) (Table 4).
There was a statistically signiﬁcant positive correlation be-
tween serum nitric oxide and CIMT (r= 0.766) (P= 0.000),
as well as a statistically signiﬁcant negative correlation between
serum nitric oxide and FMD (r= 0.883) (P= 0.000)
(Table 4).
There was a statistically signiﬁcant positive correlation be-
tween CIMT and TSH (r= 0.725) (P= 0.000), age
(r= 0.566) (P= 0.000), waist circumference (r= 0.253)
(P= 0.011), Total cholesterol (r= 0.630) (P= 0.000), LDL
cholesterol (r= 0.689) (P= 0.000), anti-TPO antibodies
(r= 0.566) (P= 0.000) and serum nitric oxide (r= 0.766)
(P= 0.000), while there was statistically signiﬁcant negative
correlation between CIMT and F.T4 (r= 0.749)
(P= 0.000) (Table 4).
There was statistically signiﬁcant negative correlation be-
tween FMD and TSH (r= 0.910) (P= 0.000), anti-TPO
antibodies (r= -0.529) (P= 0.000), total cholesterol
(r= 0.826) (P= 0.000), LDL cholesterol (r= 0.911)
(P= 0.000) and TG (r= 0.288) (P= 0.004), and serum ni-
tric oxide (r= 0.883) (P= 0.000), while there was a statisti-
cally signiﬁcant positive correlation between FMD and F.T4
(r= 0.799) (P= 0.000) (Table 4).
All the correlations were made for all subjects in all studied
groups.P 0.000 0.000 0.000
Anti-TG
r 0.240(*) 0.435(**) 0.301(**)
P 0.024 0.000 0.004
Anti-TPO
r 0.474(**) 0.566(**) 0.529(**)
P 0.000 0.000 0.000
NO
r 1 0.766(**) 0.883(**)
P 0.000 0.000
* Correlation is signiﬁcant at the 0.05 level (2-tailed).
**4.1. Multivariate analysis of different factors which affect
CIMT
Multivariate analysis showed that the diagnosis of Hashimoto
thyroiditis is independent of thyroid function, age, WC and
dyslipedemia affected or ‘‘predicted’’ CIMT (P= 0.015).
There are other factors affecting CIMT in the same model
which are age (P= 0.000), waist circumference (P= 0.000),
F.T4 (P= 0.027) and interestingly serum nitric oxide
(P= 0.000) (Table 5).
Correlation is signiﬁcant at the 0.01 level (2-tailed).
Table 5 Multivariate analysis of different factors which affect CIMT in patients with hypothyroidism.
Model Unstandardized coeﬃcients Standardized coeﬃcients t Sig.
B Std. error Beta
1
Constant 0.264 0.069 3.845 0.000
Diagnosis 0.009 0.004 0.115 2.468 0.015
WC 0.002 0.000 0.115 4.034 0.000
TC 5.800E07 0.000 0.000 0.003 0.998
LDL 0.000 0.000 0.110 1.111 0.270
Age 0.006 0.000 0.497 17.441 0.000
F.T4 0.004 0.002 0.122 2.242 0.027
TSH 0.001 0.001 0.098 0.995 0.322
Anti-TPO 0.000 0.000 0.081 2.401 0.018
NO 0.001 0.000 0.362 5.779 0.000
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Multivariate analysis showed that the diagnosis of Hashimoto
thyroiditis is independent of thyroid function, age and dyslip-
edemia affected or predicted FMD (P= 0.000), other factors
affecting FMD in the same model are LDL cholesterol
(P= 0.000), F.T4 (P= 0.046) and interestingly serum nitric
oxide (P= 0.000) (Table 6).
5. Discussion
5.1. Markers of subclinical atherosclerosis in hypothyroidism
Our results show that CIMT is signiﬁcantly higher in overt
hypothyroidism compared to control and correlated positively
to TSH and negatively to F.T4. Univariate analysis showed
that CIMT was also correlated to age, WC, total cholesterol,
LDL cholesterol and serum nitric oxide.
Regarding the effect of the cause of hypothyroidism on
CIMT, we observed a trend toward higher values of CIMT
in HT compared to post-thyroidectomy and post-RAI that
was not statistically signiﬁcant; however, multivariate analysis
showed that HT; independent of age, WC, F.T4 and NO; pre-
dicted CIMT with statistical signiﬁcance.
In accordance with our work, Nagasaki et al. and Kim et al.
showed that both overt and subclinical hypothyroidism in-
creased CIMT. They explained this by an atherogenic lipid
proﬁle as both increased CIMT and dyslipidemia were revers-
ible after achieving euthyroidism. They also suggested other
explanations like low grade inﬂammation and activation of
the immune system by Hashimoto thyroiditis.59,60
Takamura et al. showed that TSH, as well as fT4, within
normal reference range, was signiﬁcantly correlated with
CIMT after adjustment for known cardiovascular risk
factors.61
On the other hand, Cabral et al. showed that there is no sig-
niﬁcant difference observed with respect to CIMT between the
SCH and control groups. The explanation was that they chose
subjects who were matched with respect to age, BMI, smoking,
menopausal status, and lipid proﬁle.62
5.2. Markers of endothelial dysfunction
Our results show that FMD is signiﬁcantly lower in overt and
hypothyroidism compared to the control and correlatednegatively to TSH and positively to F.T4, univariate analysis
showed that FMD was also correlated to age, anti-TPO anti-
bodies, total cholesterol, LDL cholesterol and serum nitric
oxide.
Regarding the effect of the cause of hypothyroidism on
FMD, we observed that FMD was signiﬁcantly lower in HT
compared to post-thyroidectomy and post-RAI; also, multi-
variate analysis showed that HT, independent of LDL-C,
F.T4 and NO, predicted FMD with statistical signiﬁcance.
In accordance with our work, Clausen et al. and Taddei
et al. showed that both overt and subclinical hypothyroidism
were associated with endothelial dysfunction and impaired
FMD. They explained this partly by mild dyslipidemia as
endothelial dysfunction persisted even after achieving euthy-
roidism and normolipidemia. They attributed this to the fact
that most of their patients were HT and that autoimmune pro-
cess may still be active in these patients despite levothyroxine
substitution and this process could maintain the endothelial
dysfunction despite euthyroidism.63,64
Vo¨lzke et al. showed that serum TSH levels within the
upper reference range are associated with impaired endothelial
function. They recommended that upper TSH reference limit
should be redeﬁned.65
On the other hand, Cabral et al. showed that there is no sig-
niﬁcant difference observed with respect to FMD between the
SCH and control groups. The explanation was that they se-
lected subjects who were matched with respect to age, BMI,
smoking, menopausal status, and lipid proﬁle.62
5.3. Markers of oxidative stress
Reactive oxygen species (ROS) consist of superoxide anion
(O2 ), hydrogen peroxide (H2O2) and hydroxyl radical (OH
),
and increased free-radical production leads to oxidative stress
with the formation of self-propagating lipid peroxidation.
Primary defense against oxidative stress includes the antiox-
idant enzymes super oxide dismutase (SOD), glutathione per-
oxidase (GSHPx) and catalase (CAT). These ROS interact
with nucleic acids, proteins and lipids causing cellular dysfunc-
tion and even death.66
Nitric oxide (NO) is produced by the enzyme NO synthase
(NOS). NOS occurs in three forms: endothelial (e) (NOS3),
neuronal (n) (NOS1) and inducible (i) (NOS2). The ﬁrst two
are constitutively expressed c-NOS. In general, n- and e-
NOS release NO in the nM range whereas i-NOS, following
Table 6 Multivariate analysis of different factors which affect FMD in patients with hypothyroidism.
Model Unstandardized coeﬃcients Standardized coeﬃcients t Sig.
B Std. Error Beta
1
Constant 21.819 1.310 16.650 0.000
Diagnosis 0.458 0.084 0.201 5.440 0.000
TG 0.002 0.003 0.024 0.700 0.486
TC 0.001 0.006 0.011 0.147 0.884
LDL 0.066 0.009 0.617 7.126 0.000
F.T4 0.079 0.039 0.084 2.028 0.046
TSH 0.006 0.018 0.026 0.324 0.747
Anti-TPO 0.002 0.002 0.023 0.926 0.357
NO 0.036 0.005 0.394 7.744 0.000
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for extended periods of time (often called a high-output source
of NO).44
NO derived from c-NOS may occur in two functional
forms: the ﬁrst is always present at low ‘tonal’ or ‘basal’ levels
which serve to dampen or control the threshold for activation
of vascular and immune cells in response to nonspeciﬁc stim-
uli, i.e. homeostatic, and an enhanced release in response to
certain signals, e.g., acetylcholine (ACH). This brief and en-
hanced release of c-NOS-derived NO can have profound phys-
iological actions, e.g. endothelium-dependent vasodilation,
whereas i-NOS is induced by various signal molecules, e.g.
proinﬂammatory cytokines.67.
NO, derived from c-NOS, may tonically inhibit i-NOS
activity through NF-kB under non-stimulated conditions.
However, if the proinﬂammatory event was extremely strong,
i-NOS induction probably cannot be diminished.67
NO has a role as a neurotransmitter and a regulator of
blood pressure, it has vasodilator and antiplatelet, tumoricidal,
and microbicidal activities.68 NO is converted under aerobic
conditions to nitrite, and low concentrations of nitrite inhibit
myeloperoxidase-mediated oxidation of LDL. NO also acts
as an antioxidant by scavenging alkoxyl and peroxyl radicals.
When NO is in excess of the surrounding oxidants, lipid oxida-
tion and monocyte margination into the vascular wall are
attenuated, producing anti-atherogenic effects.43
ROS can reduce NO bioavailability in endothelium by three
mechanisms: (1) in the presence of O by the formation of per-
oxynitrite, (2) inhibition of e-NOS, and (3) uncoupling of e-
NOS with decreased NO and increased O production, this
is followed by endothelial dysfunction and atherogenesis.69
Every time NO and superoxide collide, they form peroxyni-
trite non-enzymatically and very rapidly. Under proinﬂamma-
tory conditions, simultaneous production of superoxide and
NO can be strongly activated to increase production 1000-fold,
which will increase the formation of peroxynitrite by a
1000,000-fold.62
The peroxynitrite anion (ONOO2) is an effective means of
producing hydroxyl radical OH, which oxidizes LDL.43 Per-
oxynitrite may contribute to endothelial dysfunction by various
mechanisms including: (1) triggering apoptosis and/or necrosis
in endothelial and vascular smooth muscle cells, (2) inducing
upregulation of adhesion molecules in endothelial cells, (3)
enhancing neutrophils adhesion and other mechanisms.69
Furthermore, clinically relevant concentrations of 3-
nitrotyrosine, a marker of peroxynitrite load, result in concen-tration-dependent impairment of acetylcholine-induced, endo-
thelium-dependent vascular relaxation. Numerous studies have
demonstrated increased 3-nitrotyrosine and i-NOS expression
in human atherosclerotic tissue, which correlated with plaque
instability in patients.62
i-NOS-derived peroxynitrite has a central component of
inﬂammation. Expression of inducible NOS, which is associ-
ated with increased peroxynitrite production, resulted in in-
creased apoptotic cell death in atheromatous plaques of
human coronary arteries.43,44
Our results show that serum NO is signiﬁcantly higher in
overt hypothyroidism compared to the control and correlated
positively to TSH and negatively to F.T4, univariate analysis
showed that NO was also correlated to anti-TPO antibodies,
total cholesterol, LDL cholesterol.
Regarding the effect of the cause of hypothyroidism on ser-
um NO, we observed that NO was not signiﬁcantly different in
the three studied groups of overt hypothyroidism; also, both
univariate and multivariate analyses of different factors which
affect CIMT and FMD showed that NO was an independent
predictor of both FMD and CIMT.
Coria et al. showed somewhat similar results to ours, they
proved that NO concentration signiﬁcantly increased in overt
hypothyroidism compared to the euthyroidism. Also NO in
SCH tends to increase, though this was not signiﬁcant com-
pared to euthyroidism.70
Moustafa et al. demonstrated that serum total T3 showed
negative correlation with serum NO, in a similar way we dem-
onstrated a negative relation between F.T4 and NO. They ex-
plained their ﬁnding by the antioxidant function of thyroid
hormones in two ways: by increasing ATP cycling, which en-
hances oxidative phosphorylation and decreases the formation
of ROS and by increasing the supply of NADPH necessary for
the regeneration of reduced glutathione (GSH), thus facilitat-
ing the scavenging of ROS.71
Kumari et al., unlike our results, showed that serum nitric
oxide exhibits almost no change in hypothyroidism when com-
pared to the normal levels.72 Ozcan et al. on the other hand
demonstrated that the NO levels in serum of the hypothyroid
were lower than in the euthyroid controls.73
The apparent discrepancy in our results between impaired
FMD (denoting impaired e-NOS derived NO availability)
and increased serum NO can be resolved by the following
arguments.
Virdis et al. demonstrated a signiﬁcant i-NOS induction, to-
gether with an increased superoxide production, and impaired
274 M.N. Atta et al.endothelium-dependent relaxation in hypothyroidism. All
these changes were reversible by i-NOS blockade and
antioxidants.
These ﬁndings suggest opposing effects of hypothyroidism
on i-NOS and e-NOS where there is an induction of i-NOS
with increased NO and O (hence peroxynitrite formation),
and down regulation of e-NOS with loss of tonal and stimu-
lated c-NOS derived NO leading to non-dampening of vascu-
lar and immune cells activation and loss of endothelium-
dependent vasodilation.74
A second argument to resolve discrepancy is that endothe-
lial-dependent vasodilation EDV may not be NO dependent
after all; supporting this hypothesis raised by Tschakovsky
and Pyke are the following observations.
With an increase in shear stress at least three vasodilators
are known to increase (NO, prostacyclin, endothelium-derived
hypopolarizing factor). The FMD response to more sustained
stimuli was mediated by NO-independent mechanism(s).
Accordingly, FMD in response to sustained shear stress may
constitute a critical component of endothelial function for
which NO may not be obligatory. Shear stimulus also evokes
a potent vasoconstrictor, endothelin. Thus alterations in endo-
thelin release by the vascular endothelium would be expected
to inﬂuence FMD.
Taken together, the common assumption that FMD repre-
sents NO-mediated endothelial function may be misleading in
understanding endothelial function.75
To our knowledge, this is the ﬁrst study to show that HT is
an independent cardiovascular risk factor in clinically hypo-
thyroid patients, Bilir et al. found no statistically signiﬁcant
difference regarding CIMT between 59 hypothyroid patients
classiﬁed according to the cause of hypothyroidism; HT, post-
surgical and post-radioiodine.
Possible mechanisms explaining the increased cardiovascu-
lar risk in Hashimoto thyroiditis
1. Low grade chronic inﬂammation leading to endothelial
dysfunction: the association between low grade inﬂamma-
tion and endothelial function was demonstrated by Taddei
et al., they showed that COX-2 dependent low grade
inﬂammation as evidenced by high hs-CRP and IL-6 in
patients with SCH due to Hashimoto thyroiditis causes
impairment of endothelium-dependent vasodilation.76Tad-
dei et al. proposed two possible mechanisms for systemic
inﬂammation: high TSH itself may induce inﬂammation
as evidenced by its ability to induce TNF-a production,
but the persistence of impaired EDV even after L-thyroxine
replacement and achieving euthyroidism precludes this
explanation. The second and more accepted mechanism is
the chronic stimulation of the immune system by Hashim-
oto thyroiditis, the persistence of only elevated ESR and
thyroid Abs after achieving euthyroidism proves a role
for Hashimoto thyroiditis in the residual endothelial
dysfunction.64
2. Increased oxidative stress: in the aforementioned study by
Taddei et al., they demonstrated that vitamin C (an antiox-
idant compound capable of scavenging superoxide anions
at high concentrations) signiﬁcantly improved EDV. They
suggested that oxidative stress may be the pathogenetic
mechanism linking inﬂammation to endothelial dysfunc-
tion.76Gerenova et al. demonstrated lower activities of Cat-
alase and Glutathione peroxidase in euthyroid Hashimotothyroiditis, suggesting an increased oxidative stress.77In
addition, our work showed that nitric oxide as a marker
of oxidative stress was an independent predictor of both
CIMT and FMD in clinically hypothyroid patients.
Evidence from clinical trials linking euthyroid Hashimoto
thyroiditis to increased cardiovascular risk and impaired
health status demonstrated the following observations: (1) in-
creased CIMT in overweight and obese women probably due
to decreased immune tolerance in obesity, (2) increased IL-6,
a key cytokine in atherosclerosis, (3) lower endothelial-depen-
dent arterial dilation linked to autoimmunity and elevated
LP(a), (4) impaired right and left ventricular function and car-
diac autonomic dysfunction, (5) increased arterial stiffness in
women and ﬁnally (6) decreased quality of life and early preg-
nancy loss.78–83
Staii et al. recently reported that euthyroid cytology proven
HT has a similar prevalence to that of type 2 diabetes.84
In conclusion, to our knowledge, this is the ﬁrst study to
show that HT is an independent cardiovascular risk factor. Gi-
ven its high prevalence, HT may have an impact on cardiovas-
cular health that is more or less similar to that of type 2
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